(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
20 January 2011 (20.01.2011)

PCT

(10) International Publication Number
WO 2011/006915 A2

(51) **International Patent Classification**:
C07K 16/18 (2006.01)

(21) **International Application Number**:
PCT/EP2010/060112

(22) **International Filing Date**:
14 July 2010 (14.07.2010)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
61/226,028 16 July 2009 (16.07.2009) US
61/307,554 24 February 2010 (24.02.2010) US

(71) **Applicant** *(for all designated States except US)*: **GLAXO GROUP LIMITED** [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford Middlesex UB6 0NN (GB).

(72) **Inventors; and**

(75) **Inventors/Applicants** *(for US only)*: **COULSTOCK, Edward** [GB/GB]; Domantis Limited, 315 Cambridge Science Park, Cambridge Cambridgeshire CB4 0WG (GB). **DE ANGELIS, Elena** [GB/GB]; Domantis Limited, 315 Cambridge Science Park, Cambridge Cambridgeshire CB4 0WG (GB). **LIU, Haiqun** [CN/GB]; Domantis Limited, 315 Cambridge Science Park, Cambridge Cambridgeshire CB4 0WG (GB). **SCHON, Oliver** [DE/GB]; Domantis Limited, 315 Cambridge Science Park, Cambridge Cambridgeshire CB4 0WG (GB).

(74) **Agents**: **CLUBE, Jasper Rupert** et al.; GlaxoSmithKline, Global Patents CN925.1, 980 Great West Road, Brentford Middlesex TW8 9GS (GB).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

— *of inventorship (Rule 4.17(iv))*

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

(54) **Title**: IMPROVED ANTI-SERUM ALBUMIN BINDING SINGLE VARIABLE DOMAINS

(57) **Abstract**: The invention relates to improved anti-serum albumin immunoglobulin single variable domains, as well as ligands and drug conjugates comprising such variable domains, compositions, nucleic acids, vectors and hosts.

WO 2011/006915 A2